VEGFA and cancer: Given this perspective, two classes of drugs have been approved for the treatment of cancers: the monoclonal antibody Bevacizumab (Avastin®, Roche), which targets and neutralizes VEGF, and VEGF-linked tyrosine kinase inhibitors (TKIs), including Sorafenib (Nexavar®, Bayer-Onyx Pharmaceuticals), Cediranib (Recentin, AstraZeneca) and Sunitinib (Sutent®, Pfizer).